Build status - In Progress
Search filters

Filters
Clear All

Phase

  • 33
  • 92
  • 1
  • 77
  • 37
  • 1
  • 109
  • 372
  • 173
  • 13
  • 16
  • 343
  • 368
  • 4

Found 372 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Identification of neoantigen-specific T cell responses in cancer patients within the Penn Medicine BioBank
18 years - 90 years
All genders
You are being asked to participate in this research investigation because you have expressed an interest in participating in a study to better understand how the immune cells of the body recognize and fight cancer.
99 years or below
All genders
Phase 1
This study recruits participants directly from Penn Medicine clinics, during time of their clinical biopsies. Up to 40 participants with known or suspected primary or metastatic breast cancer who meet eligibility requirements for this study will undergo FTT PET/CT study imaging. Each PET/CT scan will include an injection of up …
 AN UN-BLINDED  INTRA-PATIENT COMPARISON OF TRANSBRONCHIAL FORCEPS BIOPSY AND CRYOBIOPSY FOR PERIPHERAL PULMONARY LESIONS
99 years or below
All genders
Peripheral lung nodules seen on CT scans require a diagnostic evaluation as they commonly represent small, treatable lung cancers. In order to diagnose these lung lesions, bronchoscopy with small lung biopsies is often the preferred first step. However, this procedure is not always successful as not all biopsies obtain enough …
 COMPPARE
30 years - 80 years
All genders
This study is a comparison of patient-centric outcomes between parallel cohorts of men with prostate cancer treated using intensity-modulated radiation therapy techniques. This study includes a pre-specified randomized comparison of standard fractionation and moderate hypofractionation dose schemes within the proton therapy cohort. In addition, subgroup analyses will include a comparison …
 The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients
18 years - 99 years
All genders
The research study is being conducted secondary and after your completion of the primary study (Effect of Radiation Therapy on Sleepiness and Activity in Prostate and Breast Cancer Patients). The purpose of the current study is to assess the effectiveness of a behavioral treatment for insomnia (also known as Cognitive …
 A Randomized   Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+)  HER2 (-) Breast Cancer
18 years - 99 years
All genders
Phase 3
Interventional
The purpose of the study is to evaluate whether SAR439859 (an experimental hormonal treatment), in combination with palbociclib is a better option compared to letrozole (a standard hormonal treatment), in combination with palbociclib, in terms of efficacy and tolerance for treating patients with ER (+), HER2 (-) breast cancer. Eligible …
 UPCC 12119: An Exploratory Biomarker Study of Metastatic Triple-Negative Breast Cancer Patients Treated with Immune Checkpoint Inhibitors
18 years - 99 years
All genders
Interventional
The purpose of this research is to collect clinical information and research tissue samples (blood, tissue, and stool) from patients receiving standard treatment for metastatic triple-negative breast cancer to help researchers better understand the use of immunotherapy in breast cancer.
 Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer (TNBC)
18 years - 99 years
All genders
Phase 2
Interventional
This is a randomized phase 2 open label study of sacituzumab govitecan +/- pembrolizumab for patients with PD-L1-negative (PD-L1-) metastatic triple negative breast cancer (TNBC), who have not received prior therapy for metastatic breast cancer and who have not received a prior PD-1/L1 inhibitor
 Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation (BRCA-P)
25 years - 55 years
Female
Phase 3
Interventional
This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.
99 years or below
All genders
Phase 1
LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. …
281 - 290 of 372